tPA in the central nervous system: Relations between tPA and cell surface LRPs

Recent Patents on Endocrine, Metabolic and Immune Drug Discovery

Volumn 7, Issue 1, 2013, Pages 65-76

  Ortolano, Saida ^a   Spuch, Carlos ^a  

^a UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

Author keywords

BBB; Brain diseases; CNS; LRP; Neurodegenerative diseases; Plasmin; Plasminogen; tPA

Indexed keywords

LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; TISSUE PLASMINOGEN ACTIVATOR;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CELL MEMBRANE PERMEABILITY; CELL SURFACE; CENTRAL NERVOUS SYSTEM; CEREBROVASCULAR ACCIDENT; HUMAN; MULTIINFARCT DEMENTIA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SIGNAL TRANSDUCTION;

EID: 84873171557     PISSN: 18722148     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221413804660962     Document Type: Review

References (118)

1. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/ plasmin system. J Clin Invest 1991; 88(4): 1067-72.
2. Hacke W, Kaste M, Bluhrnki E, Bozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008; 329(13): 1317-29.
3. Strickland S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost 2001; 86: 138-43.
4. Tsirka SE, Gualandris A, Amaral DG, Strickland S. Excitotoxininduced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377(6547): 340-4.
5. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129(3): 307-21.
6. Sakharov DV, Barrertt-Bergshoeff M, Hekkenberg RT, Rijken DC. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: Comparison of nine plasminogen activators in vitro. Thromb Haemost 1999; 81(4): 233-40.
7. Samson AL, Medcalf RL. Tissue-type plasminogen activator: A multifaceted modulator of neurotransmission and synaptic plasticity. Neuron 2006; 50(5): 673-8.
8. Yepes M, Lawrence DA. New functions for an old enzyme: Non haemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med 2004; 229(11): 1097-104.
9. Friedman GC, Seeds NW. Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res 1994; 81(1): 41-9.
10. Madani R, Hulo S, Toni N, Madani H, Steimer T, Muller D, et al. Enhanced hippocampal long-term potentiation and learning by increased neuronal expression of tissue-type plasminogen activator in transgenic mice. EMBO J 1999; 18(1): 3007-12.
11. Calabresi P, Napolitano M, Centonze D, Marfia GA, Gubellini P, Teule MA, et al. Tissue plasminogen activator controls multiple forms of synaptic plasticity and memory. Eur J Neurosci 2000; 12(3): 1002-12.
12. Pawlak R, Nagai N, Urano T, Napiorkowska-Pawlak D, Ihara H, Takada Y, et al. Rapid, specific and active site-catalyzed effect of tissue-plasminogen activator on hippocampus-dependent learning in mice. Neuroscience 2002; 113(4): 995-1001.
13. Rogove AD, Siao C, Keyt B, Strickland S, Tsirka SE. Activation of microglia reveals a nonproteolytic cytokine function for tissue plasminogen activator in the central nervous system. J Cell Sci 1999; 112(22): 4007-16.
14. Wu YP, Siao CJ, Lu W, Sung TC, Frohman MA, Milev P, et al. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol 2000; 148(6): 1295-304.
15. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signalling. Nat Med 2001; 7(1): 59-64.
16. Selkoe DJ. Clearing the brain's amyloid cobwebs. Neuron 2001; 32(2): 177-80.
17. Sappino AP, Madani R, Huarte J, Belin D, Kiss JC, Wohlwend A, et al. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92(2): 679-85.
18. Rogove AD, Tsirka SE. Neurotoxic responses by microglia elicited by excitotoxic injury in the mouse hippocampus. Curr Biol 1998; 8:19-25.
19. Docagne F, Nicole O, Marti HH, MacKenzie ET, Buisson A, Vivien D. Transforming growth factor-beta1 as a regulator of the serpins/t-PA axis in cerebral ischemia. FASEB J 1999; 13:1315-24.
20. Frey U, Müller M, Kuhl D. A different form of long-lasting potentiation revealed in tissue plasminogen activator mutant mice. J Neurosci 1996; 16:2057-63.
21. Baranes D, Lederfein D, Huang YY, Chen M, Bailey CH, Kandel ER. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 1998; 21(4): 813-25.
22. Vivien D, Ali C. Traumatic brain injury: Tissue-type plasminogen activator-harmful or beneficial? Nat Rev Neurol 2012; 11(8): 538-9.
23. Cassé F, Bardou I, Danglot L, Briens A, Montagne A, Parcq J, et al. Glutamate controls tPA recycling by astrocytes, which in turn influences glutamatergic signals. J Neurosci 2012; 32(15):5186-99.
24. Benchenane K, López-Atalaya JP, Fernández-Monreal M, Touzani O, Vivien D. Equivocal roles of tissue-type plasminogen activator in stroke-induced injury. Trends Neurosci 2004; 27:155-60.
25. Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997; 91:917-25.
26. Kim YH, Park JH, Hong SH, Koh JY. Nonproteolytic neuroprotection by human recombinant tissue plasminogen activator. Science 1999; 284(5414):647-50.
27. Lee HY, Hwang IY, Im H, Koh JY, Kim YH. Non-proteolytic neurotrophic effects of tissue plasminogen activator on cultured mouse cerebrocortical neurons. J Neurochem 2007; 101(5):1236-47.
28. Liot G, Roussel BD, Lebeurrier N, Benchenane K, López-Atalaya JP, Vivien D, et al. Tissue-type plasminogen activator rescues neurones from serum deprivation-induced apoptosis through a mechanism independent of its proteolytic activity. J Neurochem 2006; 98(5):1458-64.
29. Siao CJ, Tsirka SE. Tissue plasminogen activator mediates microglial activation via its finger domain through annexin II. J Neurosci 2002; 22(9): 3352-8.
30. Benchenane K, Berezowski V, Fernández-Monreal M, Brillault J, Valable S, Dehouck MP, et al. Oxygen glucose deprivation switches the transport of tPA across the blood brain barrier from an LRP-dependent to an increase LEP-independent process. Stroke 2005; 36(5): 1065-70.
31. Beliveau, R., Demuele, M., Bertrand, Y., Michaud-Levesque, J., Jodoin, J. Compound and method for regulating plasminogen activation and cell migration. EP2497485 (2012).
32. Spuch C, Ortolano S, Navarro C. LRP1 and LR2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease. Front Physiol 2012; 3: 269.
33. Kanekiyo T, Zhang J, Liu Q, Liu CC, Zhang L, Bu G. Heparan sulphate proteoglycan and the low density lipoprotein receptor related protein-1 constitute major pathways for neuronal amyloidbeta uptake. J Neurosci 2011; 31: 1644-51.
34. Fester L, Zhou L, Bütow A, Huber C, von Lossow R, Prange-Kiel J, et al. Cholesterol promoted synaptogenesis requires the conversion of cholesterol to estradiol in the hippocampus. Hippocampus 2009; 19: 692-705.
35. Andersen OM, Willnow TE. Lipoprotein receptors in Alzheimer's disease. Trends Neurosci 2006; 29: 687-94.
36. Rebeck GW, Harr SD, Strickland DK, Hyman BT. Multiple, diverse senile plaque-associated proteins are ligands of an apolipoprotein E receptor, the alpha 2-macroglobulin receptor/low-densitylipoprotein receptor related protein. Ann Neurol 1995; 37: 211-7.
37. Marzolo MP, von BR, Bu G, Inestrosa NC. Expression of alpha(2)-macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat microglial cells. J Neurosci Res 2000; 60: 401-11.
38. Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002; 71: 405-34.
39. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I. Choroid plexus megalin is involved in neuroprotection by serum insulinlike growth factor I. J Neurosci 2005; 25: 10884-93.
40. Spuch C, Navarro C. Expression and functions of LRP-2 in central nervous system: Progress in understanding its regulation and the potential use for treatment of neurodegenerative diseases. Immunol Endocr Metab Agents Med Chem 2010; 10(4): 249-54.
41. LaFerla FM, Troncoso JC, Strickland DK, Kawas CH, Jay G. Neuronal cell death in Alzheimer's disease correlates with ApoE uptake and intracellular Abeta stabilization. J Clin Invest 1997; 100: 310-20.
42. Bento-Abreu A, Velasco A, Pólo-Hernandez E, Perez-Reyes PL, Tabernero A, Medina JM. Megalin is a receptor for albumin in astrocytes and is required for the synthesis of the neurotrophic factor oleic acid. J Neurochem 2008; 106: 1149-59.
43. Alvira-Botero X, Perez-Gonzalez R, Spuch C, Vargas T, Antequera D, Garzon M, et al. Megalin interacts with APP and the intracellular adaptor protein Fe65 in neurons. Mol Cell Neurosci 2010; 45: 306-15.
44. Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995; 270(5244): 1992-4.
45. Seeds NW, Basham ME, Haffke SP. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Nat Acad Sci USA 1999; 96(24): 14118-23.
46. Salles FJ, Strickland S. Localization and regulation of the tissue plasminogen activator-plasmin system in the hippocampus. J Neurosci 2002; 22(6): 2125-34.
47. Pawlak R, Margarinos AM, Melchor J, McEwen B, Strickland S. Tissue plasminogen activator in the amygdala is critical for stressinduced anxiety-like behavior. Nat Neurosci 2003; 6(2): 168-74.
48. Seeds NW, Basham ME, Ferguson JE. Absence of tissue plasminogen activator gene or activity impairs mouse cerebellar motor learning. J Neurosci 2003; 23(19):7368-75.
49. Rodrigues SM, Schafe GE, LeDoux JE. Molecular mechanisms underlying emotional learning and memory in the lateral amygdale. Neuron 2004; 44(1): 75-91.
50. Teesalu T, Kulla A, Simisker A, Siren V, Lawrence DA, Asser T, et al. Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system. Thromb Haemost 2004; 92(2): 358-68.
51. Masos T, Miskin R. mRNAs encoding urokinase type plasminogen activator and plasminogen activator inhibitor-1 are elevated in the mouse brain following kainate-mediated excitation. Brain Res Mol Brain Res 1997; 47(1-2): 157-69.
52. Yepes M, Lawrence DA. New functions for an old enzyme: Nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp Biol Med 2004; 229(11): 1097-104.
53. Seeds NW, Verrall S, Friedman G, Hayden S, Gadotti D, Haffke S, et al. Plasminogen activators and plasminogen ectivator inhibitors in neuronal development. Ann NY Acad Sci 1992; 4(667): 32-40.
54. Lawson LJ, Perry VH, Dri P, Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990; 39(1): 151-70.
55. Bukhari N, Torres L, Robinson JK, Tsirka SE. Axonal regrowth after spinal cord injury via chondroitinase and the tissue plasminogen activator (tPA)/plasmin system. J Neurosci 2011; 31(42): 14931-43.
56. Michalski D, Hobohm C, Weise C, Pelz J, Heindl M, Kamprad M, et al. Interrelations between blood-brain barrier permeability and matrix metalloproteinases are differently affected by tissue plasminogen activator and hiperoxia in a rat model of embolic stroke. Med Gas Res 2012; 2(2): 1-5.
57. Tsirka SE, Rogove AD, Bugge TH, Degen JL, Strickland S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17(2): 543-52.
58. Indyk JA, Chen ZL, Tsirka SE, Strickland S. Laminin chain expression suggests that laminin-10 is a major isoform in the mouse hippocampus and is degraded by the tissue plasminogen activator / plasmin protease cascade during excitotoxic injury. Neuroscience 2003; 116(2): 359-71.
59. Chen ZL, Haegeli V, Yu H, Strickland S. Cortical deficiency of laminin gamma 1 impairs the AKT/GSK-3beta signaling pathway and leads to defects in neurite outgrowth and neuronal migration. Dev Biol 2009; 327(1): 158-66.
60. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic systems genes. Arterioscler Thromb Vasc Biol 1998; 18(7): 1035-45.
61. Basbaum CB, Werb Z. Focalized proteolysis: Spatial and temporal regulation of extracellular matrix degradation at the cell surface. Curr Opin Cell Biol 1996; 8(5): 731-8.
62. Gravanis I, Tsirka SE. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Tar 2008; 12(2): 159-70.
63. Spuch C, Navarro C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson' disease). J Drug Deliv 2011; 2011(469679): 1-12.
64. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 2007; 204(8): 1999-2008.
65. Barker R, Kehoe PG, Love S. Activators and inhibitors of the plasminogen system in Alzheimer's disease. J Cell Mol Med 2012; 16(4):865-76.
66. Wnendt S, Wetzels I, Gunzler WA. Amyloid beta peptides stimulate tissue-type plasminogen activator but not recombinant prourokinase. Thromb Res 1997; 85(3): 217-24.
67. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 2000; 1(6): 530-5.
68. Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abeta-induced neurodegeneration. J Neurosci 2003; 23(26): 8867-71.
69. Skrzypczak-Jankun E and Jankun J. The aflavin digallate inactivates plasminogen activator inhibitor: Could tea help in Alzheimer's disease and obesity? Int J Mol Med 2010; 26(1): 45-50.
70. Sutton ET, Hellermann GR, Thomas T. β-Amyloid-induced endothelial necrosis and inhibition of nitric oxide production. Exp Cell Res 1997; 230(2): 368-76.
71. Sutton R, Keohane ME, VanderBerg SR, Gonias SL. Plasminogen activator inhibitor-1 in the cerebrospinal fluid as an index of neurological disease. Blood Coagul Fibrinolysis 1994; 5(2): 167-71.
72. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12(12): 723-38.
73. Alvira-Botero X, Pérez-Gonzalez R, Spuch C, Vargas T, Antequera D, Garzón M, et al. Megalin interacts with APP and the intracellular adapter protein FE65 in neurons. Mol Cell Neurosci 2010; 45(3): 306-15.
74. Hastings GA, Coleman TA, Haudenschild CC, Stefanson S, Smith EP, Barthlow R, et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 1997; 272(52): 33062-7.
75. Rodriguez-Gonzalez R, Millan M, Sobrino T, Miranda E, Brea D, Perez de la Ossa N, et al. The natural tissue plasminogen activator inhibitor neuroserpin and acute ischaemic stroke outcome. Thromb Haemost 2011; 105(3): 421-9.
76. Takao M, Benson MB, Murrel JR, Yazaki M, Piccardo P, Unverzagt FW, et al. Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol 2000; 59(12): 1070-86.
77. Spuch C, Ortolano S, Navarro C. Lafora progressive myoclonus epilepsy: Recent insights into cell degeneration. Rec Pat Endocr Metab Immune Drug Discov 2012; 6(2): 99-107.
78. Yepes M, Sandkvist M, Wong MK, Coleman TA, Smith E, Cohan SL, et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96(2): 569-76.
79. Cinelli P, Madani R, Tsuzuki N, Vallet P, Arras M, Zhao CN, et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci 2001; 18(5): 443-57.
80. Madani R, Kozlov S, Akhmedov A, Cinelli P, Kinter J, Lipp HP, et al. Impaired explorative behavior and neophobia in genetically modified mice lacking or overexpressing the extracellular serine protease inhibitor neuroserpin. Mol Cell Neurosci 2003; 23(3): 473-94.
81. Vivien, D., Ali, C. Treatment of neurological or neurodegenerative disorders. EP2473185 (2012).
82. Petersen, K., Vivien, D. Treatment of neurological or neurodegenerative disorders. WO2011023249 (2011).
83. Spuch C, Navarro C. Transport mechanisms at the bloodcerebrospinal-fluid barrier: Role of megalin (LRP2). Recent Pat Endocr Metab Immune Drug Discov 2010; 4(3): 190-205.
84. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7(1): 41-53.
85. Zlokovic BV. Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci 2005; 28: 202-8.
86. Kniesel U, Wolburg H. Tight junctions of the blood-brain barrier. Cell Mol Neurobiol 2000; 20(1): 57-76.
87. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008; 57(2): 178-201.
88. Carvey PM, Hendey B, Monahan AJ. The blood brain barrier in neurodegenerative disease: A rhetorical perspective. J Neurochem 2009; 111(2): 291-314.
89. Morgan EH, Moos T. Mechanism and developmental changes in iron transport across the blood-brain barrier. Dev Neurosci 2002; 24(2-3): 106-13.
90. Dietrich MO, Spuch C, Antequera D, Rodal I, de Yebenes JG, Molina JA, et al. Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging 2008; 29(56): 902-12.
91. Bell RD, Zlokovic BV. Neurovascular mechanisms and bloodbrain-barrier disorder in Alzheimer's disease. Acta Neuropathol 2009; 118(1): 103-13.
92. Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I. Choroid plexus megalin is involved in neuroprotection by serum insulinlike growth factor I. J Neurosci 2005; 25(47): 10884-93.
93. Niego B, Freeman R, Puschmann TB, Turnley AM, Medcalf RL. T-PA-specific modulation of a human BBB involves plasmin mediated activation of the Rho-kinase pathway in astrocytes. Blood 2012; 119(20): 4752-60.
94. Correa F, Gauberti M, Parcq J, Macrez R, Hommet Y, Objiang P, et al. Tissue plasminogen activator prevents white matter damage following stroke. J Exp Med 2011; 208(6): 1229-42.
95. Gasche Y, Soccal PM, Kanemitsu M, Copin JC. Matrix metalloproteinases and diseases of the central nervous system with a special emphasis on ischemic brain. Front Biosci 2006; 11: 1289-301.
96. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 2009; 8(2): 205-16.
97. McCawley LJ, Matrisian LM. Matrix metalloproteinases: They're not just for matrix anymore. Curr Opinion Cell Biol 2001; 13(5): 534-40.
98. Ning M, Chopp M, Yan T, Zacharek A, Zhang C, Roberts C, et al. Tissue plasminogen activator treatment of stroke in type-1 diabetes rats. Neuroscience 2012; 222: 326-32.
99. Mishiro K, Ishiguro M, Suzuki Y, Tsuruma K, Shimazawa M, Hara H. A broad-spectrum matrix metalloproteinase inhibitor prevents hemorrhagic complications induced by tissue plasminogen activator in mice. Neuroscience 2012; 205: 39-48.
100. Benchenane K, Berezowski V, Ali C, Fernández-Monreal M, López-Atalaya JP, Brillault J, et al. Tissue-type plasminogen activator crosses the intact blood-brain barrier by low-density lipoprotein receptor-related protein-mediated transcytosis. Circulation 2005; 111(17): 2241-49.
101. Yao Y, Tsirka SE. Truncation of monocyte chemoattractant protein 1 by plasmin promotes blood-brain barrier disruption. J Cell Sci 2011; 124(9): 1486-95.
102. Lukic-Panin V, Deguchi, K, Yamashita T, Shang J, Zhang X, Tian F, et al. Free radical scavenger edaravone administration protects against tissue plasminogen activator induced oxidative stress and blood brain barrier damage. Curr Neurovasc Res 2010; 7(4): 319-29.
103. Lawrence, D.A., Yapes, M.S., Strickland, D.M. Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (TPA) inhibitors useful therein. US20050019329 (2005) & US20087375076 (2008).
104. Lawrence, D.A., Yapes, M.S., Strickland, D.M. Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (TPA) inhibitors useful therein. US20050019329 (2005).
105. Jianning, L., Jing, Z., Haitao, Z. Treatment effect of tissue plasminogen activator kringle-2 on stroke and preparation method for tissue plasminogen activator kringle-2. CN101886066 (2007).
106. Sohngen, M., Ebel, A., Al-Rawi, Y. Use of plasminogen activator (desmoteplase) in the treatment of stroke. NZ584640 (2012).
107. Eugen-Olsen, J., Haugaard, S., Andersen, O. Soluble urokinase plasminogen receptor (suPAR) as diagnostic marker for low-grade inflammation. EP2500730 (2012).
108. Anderberg, J., Gray, J., McPherson, P., Nakamura, K. Methods and compositions for diagnosis and prognosis of renal injury and renal failure. US2012231472 (2012).
109. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112(10): 1533-40.
110. Zhang C, An J, Strickland DK, Yepes M. The low density lipoprotein receptor related protein 1 mediates tissue-type plasminogen activator induced-microglial activation in the ischemic brain. Am J Pathol 2009; 174(2): 586-94.
111. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem 2006; 281 (4): 2120-7.
112. Wang X, Lee SR, Arai K, Lee SR, Tsuji K, Rebeck GW, et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003; 9(10): 1313-7.
113. Hu K, Lin L, Tan X, Yang J, Bu G, Mars WM, et al. tPA protects renal interstitial fibroblasts and myofibroblasts from apoptosis. J Am Soc Nephr 2008; 19: 503-14.
114. Skrzypiec AE, Buczko W, Pawlak R. Tissue plasminogen activator in the amygdale: A new role for an old protease. J Physiol Pharmacol 2008; 59(8): 135-46.
115. Qian Z, Gilbert ME, Colicos MA, Kandel ER, Kuhl D. Tissueplasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993; 361 (6411): 453-7.
116. Spuch C, Ortolano S, Navarro C. LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease. Front Physiol 2012; 3:269.
117. An J, Zhang C, Polavarapu R, Zhang X, Zhang X, Yepes M. Tissue-type plasminogen activator and the low-density lipoprotein receptor-related protein induce Akt phosphorylation in the ischemic brain. Blood 2008; 112(7): 2787-94.
118. Zhuo M, Holtzman DM, Li Y, Osaka H, DeMaro J, Jacquin M, et al. Role of tissue plasminogen activator receptor LRP in hippocampal long-term potentiation. J Neurosci 2000; 20(2): 542-9.